39.74

3.40% -1.40

After Hours: 39.74

Structure Therapeutics Inc Adr (GPCR)

Overview News Price History Option Chain Financials Why GPCR Down? Discussions Forecast

Structure Therapeutics Inc Adr stock is traded at $39.74, with a volume of 824.29K. It is down -3.40% in the last 24 hours and down -7.56% over the past month. Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Previous Close:

$41.14

Open:

$40.84

24h Volume:

824.29K

Relative Volume:

1.26

Market Cap:

$2.27B

Revenue:

Net Income/Loss:

$-100.44M

P/E Ratio:

-18.50

EPS:

-2.1478

Net Cash Flow:

$-105.32M

1W Performance:

+6.14%

1M Performance:

-7.56%

6M Performance:

+1.15%

1Y Performance:

-43.13%

1-Day Range:

$39.40

$42.22

1-Week Range:

$37.24

$42.57

52-Week Range:

$26.61

$72.16

Structure Therapeutics Inc Adr Stock (GPCR) Company Profile

Name

Structure Therapeutics Inc Adr

Sector

Healthcare (1180)

Industry

Biotechnology (680)

Phone

(628) 229-9277

Address

611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO

Employee

136

Twitter

Next Earnings Date

Latest SEC Filings

GPCR's Discussions on Twitter

Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-21-24	Initiated	JP Morgan	Overweight
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	JMP Securities	Mkt Outperform
Jul-27-23	Initiated	Piper Sandler	Overweight
May-25-23	Resumed	Jefferies	Buy
Feb-28-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	Guggenheim	Buy
Feb-28-23	Initiated	Jefferies	Buy
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Structure Therapeutics Inc Adr Stock (GPCR) Latest News

Nov 03, 2024

abrdn plc Has $9.53 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Ballard Power Systems Inc (NASDAQ: BLDP) Has Great Upside Potential - Stocks Register

Nov 01, 2024

Is Structure Therapeutics Inc ADR (NASDAQ: GPCR) A Good Investment For New Investors Now? - Stocks Register

Nov 01, 2024

Oct 31, 2024

Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic

Oct 30, 2024

Oct 28, 2024

Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21 - Business Wire

Oct 28, 2024

Oct 26, 2024

Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80 - MarketBeat

Oct 26, 2024

Oct 24, 2024

GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive

Oct 24, 2024

Oct 17, 2024

Griffin Asset Management Inc. Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Oct 17, 2024

Oct 16, 2024